Cystatin C vs. Creatinine for GFR Estimation

Basics of Each Marker

• Muscle mass (age, sex, race, amputation, malnutrition, cachexia)
• Dietary intake (high meat intake raises creatinine; vegetarian diet lowers it)
• Medications inhibiting tubular secretion (e.g., trimethoprim, cimetidine)

Estimating Equations

Accuracy Comparison

• eGFR creatinine (CKD-EPI) alone performs well for the vast majority of patients and is the recommended first-line test. It is precise, widely available, and inexpensive.
• eGFR cystatin C alone is not superior to eGFR creatinine when both use properly standardized assays. — Brenner and Rector's The Kidney, p. 4005
• eGFR combining both markers is more accurate than either alone — this is the most consistent finding across studies. — Comprehensive Clinical Nephrology 7e, p. 2145; Tietz Textbook, p. 901
• Cystatin C-based equations give improved risk prediction for death and kidney failure beyond what GFR accuracy alone explains — possibly because non-GFR determinants of cystatin C (e.g., inflammation) are themselves prognostically important. — Tietz Textbook, p. 289–291

Non-GFR Determinants (Sources of Bias)

When to Use Cystatin C — KDIGO Guidance

1. Start with creatinine-based eGFR (CKD-EPI creatinine) for routine screening.
2. Add cystatin C for confirmatory testing in adults with eGFRcr 45–59 mL/min/1.73 m² who have no other markers of kidney damage — to distinguish true CKD from a falsely low eGFR due to reduced muscle mass.
3. If eGFRcys or eGFRcr-cys < 60, CKD diagnosis is confirmed.
4. For individual clinical decisions (drug dosing, staging) where precision matters, the combined creatinine–cystatin C equation is preferred.

Special Populations

Practical Limitations of Cystatin C

• Cost — assay is 3–10× more expensive than creatinine
• Standardization — although ERM-DA471/IFCC reference material exists, multicenter evaluations show many commercial assays still fail acceptable performance criteria. — Tietz Textbook, p. 271
• Availability — not universally available in all labs, especially in low-resource settings
• Non-GFR confounders — as listed above, still subject to bias in inflammatory states

Bottom Line

Topical Minoxidil + Finasteride Spray — Application Guide

Background

Step-by-Step Application

• Apply to a dry or slightly damp scalp — not wet. Wet hair dilutes the solution and reduces contact with the scalp skin.
• Part your hair in sections to expose scalp in the areas of thinning.

• Crown/vertex — most responsive to minoxidil
• Frontal hairline / midscalp part line — also treat, though vertex responds best
• Temporal regions — include if thinning is present

• Hold the nozzle 1–2 cm from the scalp, not the hair.
• Spray directly onto the scalp, parting hair as you go to ensure scalp contact.
• Use 1 mL per application for a 5% solution (equals 1 full dropper, or approximately 6 sprays with a standard pump, depending on the device).
• Work across all affected zones using additional parts; lift sections of hair to expose scalp between each spray.
• Do not spray onto the hair shaft — the active ingredient works at the follicular level, not on hair fibers.

• Use your fingertips (not nails) to gently massage the solution across the scalp.
• Distributing evenly ensures contact with all follicles in the treated area.
• Wash hands immediately after — minoxidil can cause unwanted hair growth if absorbed through finger skin; finasteride should not be handled by pregnant women.

• Allow at least 4 hours (ideally overnight) before washing your hair.
• Do not cover with a hat or helmet immediately after application — occlusion may increase systemic absorption.
• Style your hair normally once dry; the solution is generally invisible when dried.

Dosing Schedule

What to Expect

• Shedding in the first 3–6 weeks is normal and expected — minoxidil pushes telogen (resting) hairs out to make room for new anagen hairs. Do not stop treatment for this reason. — Dermatology 5e, p. 2953
• Efficacy assessment: Treat for at least 6 months before judging effectiveness. — Goldman-Cecil, p. 4334
• Maintenance is mandatory: Stopping minoxidil causes acute telogen effluvium 3–4 months later; stopping finasteride causes gradual return to pretreatment hair density within ~1 year. — Goldman-Cecil, p. 4334

Key Precautions

• Women of childbearing age: Finasteride has teratogenic potential (male fetal genital malformation). Contraception is required; topical finasteride should not be used during pregnancy.
• Scalp conditions: Do not apply to irritated, broken, or inflamed skin — increases systemic absorption of minoxidil, which can cause hypotension, especially in patients with cardiac disease. — Katzung Pharmacology 16e, p. 1927
• PSA adjustment: If on finasteride (including topical), PSA values should be doubled for prostate cancer screening purposes. — Dermatology 5e, p. 2957
• Cardiovascular patients: Even topical minoxidil carries a small risk of systemic absorption — monitor blood pressure in at-risk patients. — Katzung, p. 1927

Topical vs Oral Finasteride

The occipital/back scalp in AGA

• Male pattern (Hamilton-Norwood): Recession affects the frontal hairline, temporal areas, vertex/crown. The back and sides (occipital and parietal fringe) are the DHT-resistant "donor zone" — these follicles are genetically programmed not to miniaturize. This is why they're used as the donor area in hair transplants.
• Female pattern (Ludwig/Sinclair): Diffuse thinning over the central part line and top of scalp, usually sparing the occipital region.

So should you apply to the back?

Why it matters

• Wastes product — no therapeutic benefit where follicles are healthy
• Increases total absorbed dose — slightly elevates systemic minoxidil exposure
• Does not cause harm to those follicles, but also won't stimulate extra growth in already-healthy hair

Practical rule